60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating the Company has regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
Related news for (SXTP)
- 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
- 24/7 Market News Snapshot 15 July, 2025 – 60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP)
- 60 Degrees Pharmaceuticals Targets Human and Canine Babesiosis Markets With Tafenoquine
- Today’s Top Performers: MoBot’s Market Review 07/15/25 07:00 AM
- 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion